Loading…
← CockpitCompetitor Analysis › ROIV Roivant Sciences Ltd.Open in the cockpit ↗

Roivant Sciences Ltd.ROIVCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech holding company that creates and funds separate subsidiaries ('Vants') to develop and commercialize individual drugs.

Momentum leader 81
Mkt cap
$28.1B
US dollars, full cap
Free float
73%
of shares outstanding
$/day
$319M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-109.3 pp
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
89 days
15 Feb 2027
Close · USD$38.73
1D+0.1%
1W-7.5%
1M+10.9%
3M+5.1%
6M+19.5%
YTD+78.5%
1Y+88.4%
ATR %3.9%
Beta1.12
52w lowhigh8.9% off high

What Roivant Sciences does

Biotech holding company that creates and funds separate subsidiaries ('Vants') to develop and commercialize individual drugs.

Creates subsidiaries around single drugs and funds them from the parent, then makes money by selling or partnering them, as with the 2023 sale of Telavant to Roche, rather than from product sales. It holds a majority of the listed Immunovant, and of Genevant, which licenses a lipid-nanoparticle delivery technology and is in patent disputes with vaccine makers.

Products and services

  • Immunovant (autoimmune antibodies)
  • Other Vant subsidiaries
  • Drug-development capital-allocation platform

Customers

  • Investors in Vant subsidiaries
  • Physicians (via subsidiary-marketed drugs)

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech holding company
  • Multi-subsidiary drug development

What could go right

  • Successful subsidiary drug approvals/IPOs
  • Capital-efficient in-license-and-develop model

What could go wrong

  • Binary clinical-trial risk across many subsidiaries
  • Dilution from repeated subsidiary capital raises

Moat: none (process know-how). Repeatable in-licensing/spin-out playbook, but no single therapeutic moat; success rides on individual pipeline bets.

Headquarters: New York, New York, United States · Founded: 2014 · Employees: 721

Named competitors

Roivant Sciences at a glance

Size Roivant Sciences (ROIV) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $28.1B, the 391st largest of 3,085 United States companies the cockpit tracks. Shares closed at $38.73 on 18 Nov 2026.

Performance Over six months the shares gained 19.5%, against +7.6% for the median peer and -2.2% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 102.1% over the last twelve months (peer median +20.1%); the operating margin is -3,234.0% (peer median 18.7%).

Valuation It trades at 597.3× enterprise value to sales against a peer median of 4.4× (most expensive of 21).

Capital Return on invested capital runs 109.3 points below its cost of capital (11.2% WACC).

Short interest Short interest is 6.3% of the free float (30 Oct 2026).

Next results Next results expected around 15 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026ROIV 125Peer median 106
Six months, rebased to 100: Roivant Sciences against the median of its 20 peers (local-currency closes).

Roivant Sciences financials

Reported figures in USD; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$41.1M$8.26M$29.1M$32.7M$61.3M
Revenue growth—-72%-11%-47%—
Gross profit$33.9M$3.63M$20.8M$20.5M$29.2M
EBITDA-$1.33B-$1.26B-$1.11B-$814M-$1.05B
Net income-$360M-$300M-$172M$4.35B-$1.01B
Free cash flow-$33.3M-$759M-$844M-$767M-$856M
Capital expenditure-$3.05M$8.21M$4.60M$1.38M$12.7M
Total debt$107M$107M$100M$54.0M$487M

Quarterly statements and history in the cockpit →

Roivant Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%-10%0%+10%+20%INSM3692DIVISLAB45684503INCYVTRSZTSSIGBIIBALNYRPRXHLN4578SDZ180145071276688235ROIV6-month return →1-month return →
Up and to the right = strong over both horizons. Roivant Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%+200%200×400×INSM3692DIVISLAB4568ZTSSIGALNY4507ROIVRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Roivant Sciences is the large dot.

Roivant Sciences competitors and peer comparison

Head to head with its named competitors (ROIV vs LGND vs PRTC.L)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Roivant Sciences ROIV$28.1B+20%+102%-3,234%597.3×n/a
Ligand Pharmaceuticals LGND$5.98B+37%+1%14%26.3×57.7%
PureTech Health PRTC.L$378M-15%-4%-1,617%27.4×n/a

How Roivant Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Roivant Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureROIVPeer medianRank in peer set
1-month return+10.9%+2.9%4th highest of 21
6-month return+19.5%+7.6%7th highest of 21
Distance from 52-week high-8.9%-13.2%8th highest of 21
Revenue growth (TTM)+102.1%+20.1%3rd highest of 21
Operating margin-3,234.0%18.7%lowest of 21
EV / Sales597.3×4.4×most expensive of 21
ROIC minus cost of capital-109.3 pp+5.4 pp2nd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%597.3×n/an/a
Insmed INSMUnited States$26.3B+3%+240%-42%17.0×n/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%9.0×7.9%+10.8%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%23.8×47.1%+8.9%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%2.1×7.6%+17.1%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%2.2×-9.0%+11.4%
Incyte INCYUnited States$24.0B+21%+25%12%3.4×14.2%+14.0%
Viatris VTRSUnited States$23.3B+23%+5%11%2.4×11.2%+3.7%
Zoetis ZTSUnited States$34.8B+7%+1%37%4.5×-2.9%+7.2%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%3.3×28.9%+26.1%
Biogen BIIBUnited States$37.2B+34%+2%17%4.4×10.1%-5.1%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%3.9×0.5%+49.8%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%19.3×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%3.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%2.3×1.6%+11.7%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%4.2×7.5%+0.4%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%7.3×11.6%+26.8%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%10.7×37.6%+11.3%
Shionogi & 4507.TJapan$17.6B+3%+46%29%4.9×0.2%+11.0%
Jiangsu Hengrui Pharmaceuticals 1276.HKHong Kong$44.9B-24%+11%27%8.1×9.1%+2.0%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%6.3×19.1%+79.3%

Questions

Who are Roivant Sciences's main competitors?
Named competitors: Ligand Pharmaceuticals (LGND), PureTech Health (PRTC.L). The cockpit's measured peer set (industry) also includes Insmed (INSM), Hansoh Pharma (3692.HK), Divi's Laboratories (DIVISLAB.NS), Daiichi Sankyo (4568.T), Astellas Pharma (4503.T), Incyte (INCY).
Is Roivant Sciences expensive compared with its peers?
On ev / sales it trades at 597.3× against a peer median of 4.4×, most expensive of 21 in its peer set.
How has Roivant Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +19.5% against +7.6% for the median peer; over one year +88.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.